Peptides, and in particular macrocyclic peptides, are well known for their ability to disrupt protein-protein interactions (PPIs).  In this webinar, learn how DNA encoded library (DEL) screening can be used to discover peptide macrocycles that disrupt PPIs  Our speakers present a case study using the oncoprotein murine double minute 2 (MDM2). We will also highlight the …Read More >

RNA molecules are promising drug targets due to their genomic prevalence, disease involvement, and druggable complex structures. Successful examples include RNA-targeting small molecule drugs for spinal muscular atrophy (SMA), with on-going efforts in other RNA-related diseases. Here, Dr. Zhifeng Yu presents our toolbox for discovering RNA-targeting small molecules, with a focus on unique DNA-encoded libraries …Read More >

Atopic dermatitis (AD) is the most common, chronic inflammatory skin disease.  To support drug discovery research in this area, WuXi AppTec offers a broad platform of validated, in vivo AD models.  Our panel includes DNCB, DNFB, and MC903-induced AD models.  Study readouts include histopathology scoring and measurements of serum IgE levels, transepidermal water loss, and …Read More >

Cell migration, invasion, and adhesion are pivotal steps in cancer metastasis.  To support research in this field, WuXi AppTec offers in vitro transwell migration and invasion assays using multiple cell types for assessing cell migratory behavior.  In addition, our in vivo metastasis panel includes a broad range of brain, bone, and liver xenograft models covering …Read More >

WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening.  Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc reporter cell lines, and validated assays (using co-cultures of Raji or A375 tumor cells) to evaluate the activity of CARs, TCRs, and bispecific antibodies.  Leverage our portfolio of reporter cell lines to accelerate your research! …Read More >

WuXi AppTec scientists recently contributed to a study which led to the discovery and optimization of a novel series of GST inhibitors. The authors used affinity mediated DEL selection against a privileged scaffold to identify a compound with potent inhibition against SjGST and GSTM2. SAR studies, coupled with X-ray crystallography and structural analysis, revealed that …Read More >

Animal studies may provide a close approximation to humans when addressing the key challenge of clinical translatability. In the preclinical setting, new insights into disease models and mechanisms are crucial to efficacy studies. In this webinar, Dr. Deming Xu, Chief Pharmacologist, Executive Director, and Head of In Vivo Pharmacology of WuXi AppTec Discovery Biology will …Read More >

Within the PI3K family, the heterodimer protein comprising the p110-α and p85-α catalytic/regulatory subunits (encoded by PIK3CA and PIK3R1) are essential in the regulation of cellular proliferation and carcinogenesis.  To support the discovery of novel PI3K inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to accelerate hit finding and lead optimization …Read More >

Protein arginine methyltransferase 5 (PRMT5) is an enzyme which plays an essential role in a wide range of cellular processes.  PRMT5 overexpression has been implicated in many diseases, including cancer, making this protein an important drug target.  To support the discovery of novel PRMT5 inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical …Read More >